Business
Lynparza receives positive EU CHMP opinion
Lynparza receives positive EU CHMP opinion.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 6338R AstraZeneca PLC 01 March 2019 \n \n\n1 March 2019 13:45 GMT\n \nLynparza receives positive EU CHMP opinion for use in \ngermline BRCA-mutated HER2-negative advanced breast cancer\n \nAstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza (olaparib) tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.\n \nPatients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.\n \nDave Fredrickson, Executive Vice President, Oncology, said: \"Despite progress in treating patients with advanced breast cancer, there remains a significant unmet need for new treatment options. If approved, Lynparza will provide these patients with both a targeted and oral chemotherapy-free option. We now have evidence supporting the potential use of Lynparza in patients with BRCA-mutated breast, ovarian and pancreatic cancers, which demonstrates our ongoing commitment to improving patient outcomes in difficult-to-treat cancers.\"\n \nRoy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck Research Laboratories, said: \"The positive opinion from CHMP for Lynparza in this patient population is an important milestone. This decision brings us one step closer to offering a new treatment option to patients with advanced breast cancer and further underscores the critical need to identify patients' BRCA status, in addition to hormone receptor and HER2 expression status, as part of the management of this disease.\"\n \nThe positive opinion is based on data from the randomised, open-label, Phase III OlympiAD trial, which tested Lynparza against the physician's choice of chemotherapy.\n \nLynparz...